HRP20220903T1 - Seladelpar za liječenje primarnog bilijarnog kolangitisa - Google Patents

Seladelpar za liječenje primarnog bilijarnog kolangitisa Download PDF

Info

Publication number
HRP20220903T1
HRP20220903T1 HRP20220903TT HRP20220903T HRP20220903T1 HR P20220903 T1 HRP20220903 T1 HR P20220903T1 HR P20220903T T HRP20220903T T HR P20220903TT HR P20220903 T HRP20220903 T HR P20220903T HR P20220903 T1 HRP20220903 T1 HR P20220903T1
Authority
HR
Croatia
Prior art keywords
compound
seladelpar
treatment
primary biliary
biliary cholangitis
Prior art date
Application number
HRP20220903TT
Other languages
English (en)
Croatian (hr)
Inventor
Pol Boudes
Charles A. Mcwherter
Original Assignee
Cymabay Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cymabay Therapeutics, Inc. filed Critical Cymabay Therapeutics, Inc.
Publication of HRP20220903T1 publication Critical patent/HRP20220903T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Farming Of Fish And Shellfish (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HRP20220903TT 2016-05-31 2017-04-26 Seladelpar za liječenje primarnog bilijarnog kolangitisa HRP20220903T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662343688P 2016-05-31 2016-05-31
EP17722943.2A EP3463328B1 (en) 2016-05-31 2017-04-26 Seladelpar for the treatment of primary biliary cholangitis
PCT/US2017/029620 WO2017209865A1 (en) 2016-05-31 2017-04-26 Treatment of intrahepatic cholestatic diseases

Publications (1)

Publication Number Publication Date
HRP20220903T1 true HRP20220903T1 (hr) 2022-10-14

Family

ID=58699276

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20220903TT HRP20220903T1 (hr) 2016-05-31 2017-04-26 Seladelpar za liječenje primarnog bilijarnog kolangitisa

Country Status (27)

Country Link
US (5) US10272058B2 (enExample)
EP (1) EP3463328B1 (enExample)
JP (1) JP7079735B2 (enExample)
KR (1) KR102408288B1 (enExample)
CN (2) CN121466055A (enExample)
AU (1) AU2017274293B2 (enExample)
BR (1) BR112018074147A2 (enExample)
CA (1) CA3024155C (enExample)
CY (1) CY1125465T1 (enExample)
DK (1) DK3463328T3 (enExample)
ES (1) ES2921230T3 (enExample)
HR (1) HRP20220903T1 (enExample)
HU (1) HUE059838T2 (enExample)
IL (1) IL263372B2 (enExample)
LT (1) LT3463328T (enExample)
MX (1) MX390417B (enExample)
NZ (1) NZ748721A (enExample)
PL (1) PL3463328T3 (enExample)
PT (1) PT3463328T (enExample)
RS (1) RS63345B1 (enExample)
RU (1) RU2765460C2 (enExample)
SG (1) SG11201810123SA (enExample)
SI (1) SI3463328T1 (enExample)
SM (1) SMT202200471T1 (enExample)
UA (1) UA122719C2 (enExample)
WO (1) WO2017209865A1 (enExample)
ZA (1) ZA201808360B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10272058B2 (en) 2014-03-20 2019-04-30 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
ES2701094T3 (es) 2014-03-20 2019-02-20 Cymabay Therapeutics Inc Tratamiento de enfermedades colestáticas intrahepáticas
US10512622B2 (en) 2017-07-14 2019-12-24 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
MX2021005724A (es) * 2018-11-16 2021-07-21 Cymabay Therapeutics Inc Tratamiento combinado contra nafld y nash.
RS65546B1 (sr) * 2021-02-01 2024-06-28 Cymabay Therapeutics Inc Tretman holangiopatija sa seladelparom
WO2024180642A1 (ja) 2023-02-28 2024-09-06 株式会社日立ハイテク プラズマ処理装置およびプラズマ処理装置の試料台の製造方法
US20260207538A1 (en) * 2024-12-20 2026-07-23 Gilead Sciences, Inc. Combinations for liver disease

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7101993B1 (en) 1990-01-11 2006-09-05 Isis Pharmaceuticals, Inc. Oligonucleotides containing 2′-O-modified purines
US7015315B1 (en) 1991-12-24 2006-03-21 Isis Pharmaceuticals, Inc. Gapped oligonucleotides
US5739135A (en) 1993-09-03 1998-04-14 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
DE69636160D1 (de) 1995-03-06 2006-06-29 Isis Pharmaceuticals Inc Verfahren zur synthese von 2'-0-substituierten pyrimidinen und oligomere davon
US6166197A (en) 1995-03-06 2000-12-26 Isis Pharmaceuticals, Inc. Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions
DK0882061T3 (da) 1996-02-14 2004-09-27 Isis Pharmaceuticals Inc Sukkermodificerede gapped oligonukleotider
US5883109A (en) 1996-07-24 1999-03-16 Bristol-Myers Squibb Company Method for lowering serum lipid levels employing an MTP inhibitor in combination with another cholesterol lowering drug
US6066653A (en) 1997-01-17 2000-05-23 Bristol-Myers Squibb Co. Method of treating acid lipase deficiency diseases with an MTP inhibitor and cholesterol lowering drugs
US7407943B2 (en) 2001-08-01 2008-08-05 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein B expression
US7511131B2 (en) 2002-11-13 2009-03-31 Genzyme Corporation Antisense modulation of apolipoprotein B expression
US7981915B2 (en) 2003-04-30 2011-07-19 Beth Israel Deaconess Medical Center Methods for modulating PPAR biological activity for the treatment of diseases caused by mutations in the CFTR gene
UA87467C2 (xx) 2003-09-19 2009-07-27 Янссен Фармацевтика Н.В 4-((феноксіалкіл)тіо)феноксіоцтова кислота та її аналоги$4-((феноксиалкил)тио)феноксиуксусная кислота и ее аналоги
PT1725234E (pt) 2004-03-05 2013-03-04 Univ Pennsylvania Métodos com efeitos secundários reduzidos para tratamento de patologias ou doenças associadas a hiperlipidemia e hipercolesterolemia
JO3006B1 (ar) 2005-09-14 2016-09-05 Janssen Pharmaceutica Nv املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك
JP5694941B2 (ja) 2008-10-17 2015-04-01 シーマベイ セラピューティクス,インコーポレイティド 小型高密度ldl粒子を減少させる方法
CN107233337A (zh) * 2009-04-29 2017-10-10 阿马里纳药物爱尔兰有限公司 含有epa和心血管剂的药物组合物以及使用其的方法
SG183529A1 (en) 2010-03-30 2012-10-30 Novartis Ag Uses of dgat1 inhibitors
JOP20200043A1 (ar) 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
HK1224186A1 (zh) 2013-11-20 2017-08-18 Cymabay Therapeutics, Inc. 纯阖家族型高胆固醇血症的治疗
US20160279085A1 (en) 2013-11-20 2016-09-29 Cymabay Therapeutics, Inc. Treatment of Severe Hyperlipidemia
US10272058B2 (en) 2014-03-20 2019-04-30 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
ES2701094T3 (es) 2014-03-20 2019-02-20 Cymabay Therapeutics Inc Tratamiento de enfermedades colestáticas intrahepáticas
CA2944139C (en) 2014-04-11 2020-11-03 Cymabay Therapeutics, Inc. Treatment of nafld and nash
CN106470675A (zh) 2014-06-26 2017-03-01 西玛贝医药公司 严重高甘油三酯血症的治疗
US10512622B2 (en) 2017-07-14 2019-12-24 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
JP7023371B2 (ja) 2017-09-26 2022-02-21 サイマベイ・セラピューティクス・インコーポレイテッド 胆汁うっ滞性そう痒の処置
MX2021005724A (es) 2018-11-16 2021-07-21 Cymabay Therapeutics Inc Tratamiento combinado contra nafld y nash.
WO2020102351A1 (en) 2018-11-16 2020-05-22 Cymabay Therapeutics, Inc. Treatment of obesity and its complications

Also Published As

Publication number Publication date
KR102408288B1 (ko) 2022-06-10
CA3024155A1 (en) 2017-12-07
JP2019518022A (ja) 2019-06-27
UA122719C2 (uk) 2020-12-28
PL3463328T3 (pl) 2022-10-03
ZA201808360B (en) 2020-02-26
US20190255004A1 (en) 2019-08-22
WO2017209865A1 (en) 2017-12-07
ES2921230T3 (es) 2022-08-22
RU2018146504A3 (enExample) 2020-07-27
US20210220305A1 (en) 2021-07-22
BR112018074147A2 (pt) 2019-03-06
CN109195594A (zh) 2019-01-11
EP3463328A1 (en) 2019-04-10
CA3024155C (en) 2023-10-10
NZ748721A (en) 2022-04-29
IL263372B2 (en) 2023-06-01
CN121466055A (zh) 2026-02-06
US10272058B2 (en) 2019-04-30
SMT202200471T1 (it) 2023-01-13
SI3463328T1 (sl) 2022-08-31
US11596614B2 (en) 2023-03-07
US20200061006A1 (en) 2020-02-27
US20170340589A1 (en) 2017-11-30
AU2017274293B2 (en) 2022-03-31
PT3463328T (pt) 2022-07-07
AU2017274293A1 (en) 2018-12-13
LT3463328T (lt) 2022-08-10
IL263372A (en) 2018-12-31
MX2018014915A (es) 2019-04-24
CY1125465T1 (el) 2025-05-09
US20210000774A1 (en) 2021-01-07
US10813895B2 (en) 2020-10-27
US10478411B2 (en) 2019-11-19
RU2018146504A (ru) 2020-07-09
SG11201810123SA (en) 2018-12-28
HUE059838T2 (hu) 2023-01-28
RU2765460C2 (ru) 2022-01-31
MX390417B (es) 2025-03-20
EP3463328B1 (en) 2022-06-15
US11000494B2 (en) 2021-05-11
RS63345B1 (sr) 2022-07-29
JP7079735B2 (ja) 2022-06-02
KR20190015363A (ko) 2019-02-13
DK3463328T3 (da) 2022-07-04

Similar Documents

Publication Publication Date Title
HRP20212010T1 (hr) Liječenje kolestatskog pruritusa sa seladelparom
HRP20210529T1 (hr) Inhibitori za mk2 i njihove uporabe
HRP20192202T1 (hr) Acc inhibitori i njihove upotrebe
HRP20241039T1 (hr) Supstituirani derivat policikličkog piridona i njegov predlijek
FI3355889T3 (fi) Diaminopyrimidiini-p2x3- ja p2x2/3-reseptorimodulaattoreita käytettäväksi yskän hoidossa
HRP20230222T1 (hr) Modulatori prolijekova integriranog puta stresa
HRP20221158T1 (hr) Sredstva za izazivanje apoptoze
HRP20220759T1 (hr) Pripravci i postupci koji ih koriste za liječenje neurodegenerativne i mitohondrijske bolesti
HRP20201946T1 (hr) Modulator regulatora transmembranske provodljivosti cistične fibroze, farmaceutski sastavi, postupci liječenja, i postupak za dobivanje modulatora
HRP20240218T1 (hr) Modulatori integriranog puta stresa
WO2016064082A3 (ko) 신규한 아미노알킬벤조티아제핀 유도체 및 이의 용도
MX2016007522A (es) Estimuladores de guanilato ciclasa soluble (sgc).
MX2018001990A (es) Composiciones que comprenden un inhibidor de p13k y un inhibidor de hdac.
CL2014000311A1 (es) Compuestos derivados de benzotiazepinas sustituidas; composicion farmaceutica que los contiene; y su uso para el tratamiento o profilaxis de la infeccion del virus sincicial respiratorio.
SV2018005682A (es) Composiciones terapeuticas para el tratamiento del virus de inmunodeficiencia humana
MX2018003569A (es) Derivados de acido oleanolico modificado en c4 para la inhibicion de il-17 y otros usos.
MX375068B (es) Un grupo de compuestos utilizados para el tratamiento o prevencion de hiperuricemia o gota.
EP3449001A4 (en) INHIBITION OF MIR-22-MIRNA BY APT-110
PH12015501940A1 (en) Dihydropyridazine-3,5-dione derivative
EA201790726A1 (ru) Фармацевтическая композиция для лечения язвенного колита
HRP20230523T1 (hr) Antitumorski agens i sredstvo za poboljšavanje antitumorskog efekta
HRP20240166T1 (hr) Postupak liječenja prader-willijevog sindroma
HRP20192235T1 (hr) SPOJEVI KORISNI ZA INHIBITIRANJE ROR-γ-T
BR112016007462A2 (pt) fitonutrientes anti-inflamatórios para uso no tratamento ou prevenção de sinovite
CL2017000230A1 (es) Composición adhesiva